 Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates ADCs for cancer patients. Mersana has developed an early-stage pipeline of 8 therapeutic programs with 2 clinical-stage therapeutics in Phase 1 XMT-1536, -1592 expected to progress quickly by FYE 2021. 